|
Volumn 25, Issue 3, 2002, Pages 278-281
|
Is there evidence-based benefit of autologous stem cell transplantation in children with solid tumors?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
ETOPOSIDE;
IFOSFAMIDE;
MELPHALAN;
CANCER ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER RISK;
CANCER STAGING;
CANCER SURVIVAL;
CHILDHOOD CANCER;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG MEGADOSE;
HIGH RISK PATIENT;
HUMAN;
MINIMAL RESIDUAL DISEASE;
NOTE;
PROGNOSIS;
SOLID TUMOR;
STEM CELL TRANSPLANTATION;
WHOLE BODY RADIATION;
ADOLESCENT;
ARTICLE;
AUTOTRANSPLANTATION;
CHILD;
CONTROLLED CLINICAL TRIAL;
EVIDENCE BASED MEDICINE;
MORTALITY;
NEOPLASM;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADOLESCENT;
CHILD;
EVIDENCE-BASED MEDICINE;
HUMAN;
NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS;
STEM CELL TRANSPLANTATION;
SURVIVAL RATE;
TRANSPLANTATION, AUTOLOGOUS;
TREATMENT OUTCOME;
HUMANS;
|
EID: 0035996226
PISSN: 0378584X
EISSN: None
Source Type: Journal
DOI: 10.1159/000064323 Document Type: Note |
Times cited : (2)
|
References (15)
|